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Novel osmotin inhibits SREBP2 via the AdipoR1/AMPK/
SIRT1 pathway to improve Alzheimer’s disease
neuropathological deﬁcits
SA Shah1,3, GH Yoon1,3, SS Chung2, MN Abid1, TH Kim1, HY Lee1 and MO Kim1
Extensive evidence has indicated that a high rate of cholesterol biogenesis and abnormal neuronal energy metabolism play key
roles in Alzheimer’s disease (AD) pathogenesis. Here, for we believe the ﬁrst time, we used osmotin, a plant protein homolog of
mammalian adiponectin, to determine its therapeutic efﬁcacy in different AD models. Our results reveal that osmotin treatment
modulated adiponectin receptor 1 (AdipoR1), signiﬁcantly induced AMP-activated protein kinase (AMPK)/Sirtuin 1 (SIRT1) activation
and reduced SREBP2 (sterol regulatory element-binding protein 2) expression in both in vitro and in vivo AD models and in Adipo− /−
mice. Via the AdipoR1/AMPK/SIRT1/SREBP2 signaling pathway, osmotin signiﬁcantly diminished amyloidogenic Aβ production,
abundance and aggregation, accompanied by improved pre- and post-synaptic dysfunction, cognitive impairment, memory deﬁcits
and, most importantly, reversed the suppression of long-term potentiation in AD mice. Interestingly, AdipoR1, AMPK and SIRT1
silencing not only abolished osmotin capability but also further enhanced AD pathology by increasing SREBP2, amyloid precursor
protein (APP) and β-secretase (BACE1) expression and the levels of toxic Aβ production. However, the opposite was true for SREBP2
when silenced using small interfering RNA in APPswe/ind-transfected SH-SY5Y cells. Similarly, osmotin treatment also enhanced the
non-amyloidogenic pathway by activating the α-secretase gene that is, ADAM10, in an AMPK/SIRT1-dependent manner. These
results suggest that osmotin or osmotin-based therapeutic agents might be potential candidates for AD treatment.
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INTRODUCTION
Alzheimer’s disease (AD) is marked by the accumulation of
intracellular tangles of insoluble hyperphosphorylated tau pro-
teins and abnormal protein deposits, or plaques, composed of
amyloid-β (Aβ) peptides (Aβ1–40 and Aβ1–42) between neurons.
These hallmarks are evident from the earliest stages of the disease,
even before symptoms of memory loss and impaired learning are
manifested. As AD progresses, memory loss and learning deﬁcits
increase as larger areas of the brain become affected by these
tangles and plaques. Late-stage severe AD is characterized by
extensive neurodegeneration, neuronal death and shrinkage of
the brain. Cholesterol homeostasis is impaired in AD. There are
several reports of an increased sterol burden in senile plaques in
AD brains of humans and rodent models.1–5 Both in vitro and
in vivo studies have shown that high levels of serum cholesterol
result in Aβ generation and therefore accelerate the progression
of AD-like pathologies.6
AMP-activated protein kinase (AMPK) is an important energy
sensor responsible for the maintenance of cellular energy
homeostasis.7 When cellular energy is depleted by stress,
starvation, hypoxia or other means, AMPK is activated allosterically
by the phosphorylation of its α-subunit on Thr-172 by upstream
kinases following an increase in intracellular AMP.8 Activated
AMPK phosphorylates downstream targets, resulting in the
inhibition of anabolic energy-consuming pathways (fatty acid
and protein synthesis) and the stimulation of energy-producing
catabolic pathways (such as fatty acid oxidation and glucose
transport) to restore cellular energy homeostasis. Sirtuins are
NAD+-dependent protein deacetylases that sense elevated NAD+
levels in response to changes in nutrient availability or stress and
regulate the expression of genes involved in energy metabolism
and the stress response. Of the seven mammalian sirtuins, sirtuin 1
(SIRT1) is the best characterized. AMPK and SIRT1 positively
regulate each other’s activities,9 allowing them to coordinate their
effects on energy metabolism.
The mammalian hormone adiponectin controls energy meta-
bolism through the AMPK/SIRT1 pathway in skeletal muscle and
liver.10 Osmotin is a tobacco protein that is structurally and func-
tionally similar to mammalian adiponectin, and its primary role in
plants seems to involve defense against pathogens.11 We recently
reported that osmotin protected against Aβ-induced memory
impairment, synaptic dysfunction and neurodegeneration in mice
and also showed protection in the developing rodent brain
against glutamate- and ethanol-induced neurodegeneration.12–14
Here, we report for the ﬁrst time that osmotin treatment reduces
cholesterol biosynthesis pathways and ameliorates the progres-
sion of Alzheimer’s disease pathologies and behavioral deﬁcits in
transgenic mice and in vitro AD models. In addition, we show that
osmotin may exert its beneﬁcial effects via the AdipoR1/AMPK/
SIRT1/SREBP2 pathways in both Adipo− /− and amyloid precursor
protein/presenilin 1 (APP/PS1) mice and in neuronal cell lines.
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MATERIALS AND METHODS
Most parts of this section are provided in the Supplementary
Information.15–18
Mouse strains
Male Adipo− /− and congenic double-transgenic B6.Cg-Tg (APPswe,
PSENdE9)85Dbo/Mmjax AD model mice were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA). The double-transgenic mice express a
chimeric mouse–human amyloid precursor protein bearing the Swedish
mutation (Mo/HuAPP695swe) and a mutant human Presenilin 1 protein
(PS1-dE9) in central nervous system neurons. Transgenic C57BL/6J-Tg
(NSE-APPsw) KLAR mice, which overexpress a mutant form of the human
amyloid precursor protein bearing the Swedish (K670N/M671L) mutation
from the neuron-speciﬁc enolase promoter, were obtained from the
Ministry of Food and Drug Safety (Cheongju, Republic of Korea). Male
C57BL/6J mice (wild type (WT)) were purchased from Samtako Bio (Osan,
Republic of Korea). Mice were housed under a 12 h light/12 h dark cycle at
25 °C with ad libitum access to food and water. The experimental procedures
were approved by the animal ethics committee of the Department of Applied
Life Sciences at Gyeongsang National University, Republic of Korea.
Osmotin treatment details in mice
Mice were grouped before treatment as follows: WT mice were randomly
divided into two groups: saline treated and osmotin treated. Transgenic
mice (single and double) were randomly divided into three subgroups:
(1) saline treated; (2) osmotin treated for a short period (12 μg per g of
body weight) two times (two consecutive days); and (3) osmotin treated
for a long period (5 μg per g of body weight) 2 times per week for 2 weeks
and 4 weeks respectively. Similarly, 3-month-old male Adipo− /− mice were
divided into two groups, that is, vehicle-treated Adipo− /− and osmotin-
treated Adipo− /− for 2 weeks. Osmotin in saline solution was administered
via intraperitoneal injection. Mice were decapitated at the age of 5, 9, 12 or
16 months.
Statistical analysis
For western blots, densities of values are expressed as the mean± s.e.m.
with arbitrary units. Prism 5 (GraphPad Software, San Diego, CA, USA) was
used for one-way analysis of variance (ANOVA) followed by Student’s t-test
for data from the western and morphological analyses and enzyme-linked
immunosorbent assays. One-way ANOVA with post hoc Tukey’s test was
used to analyze the electrophysiological data. The escape latency data
were analyzed using ANOVA with training days as repeated measurements.
For the probe tests, statistical comparisons between groups for the time
over quadrants were performed using one-way ANOVA. The data were
considered signiﬁcant at Po0.05, 0.01 and 0.001.
RESULTS
Osmotin suppressed the toxic effects of Aβ1–42 in a neuronal cell
line
First, the neuroprotective effects of osmotin against
Aβ1–42-induced toxicity in human neuroblastoma SH-SY5Y cells
were examined using an ApoTox-Glo Triplex Assay
(Supplementary Figures S1a–c). The results of the viability assay
indicated that Aβ1–42 caused a signiﬁcant decrease in cell viability,
whereas three concentrations of osmotin (0.1, 0.2 and 0.4 μM)
alone were nontoxic to the cells. In combination with Aβ1–42, all
three concentrations of osmotin signiﬁcantly increased cell
viability. Similarly, the Aβ1–42 treatment increased cytotoxicity
and caspase3/7 levels compared with an untreated control,
whereas osmotin (0.1, 0.2 and/or 0.4 μM) had no signiﬁcant effects.
When applied as cotreatment with Aβ1–42, osmotin signiﬁcantly
(Po0.001) suppressed the effects of Aβ1–42 on cytotoxicity and
caspase3/7 levels (Supplementary Figures S1a–c).
Osmotin modulated AdipoR1 and reduced Aβ via the
AMPK/SIRT1/SREBP2 pathway
We investigated the modulatory effect of osmotin on adiponectin
receptor 1 (AdipoR1) in vitro in APPswe/ind-transfected human
neuroblastoma SH-SY5Y cells treated with osmotin in the presence
or absence of AdipoR1 (small interfering RNA (siRNA) silenced). We
observed a lower expression of AdipoR1 in the APP-transfected
cells compared with the untreated control, and osmotin treatment
positively modulated the expression of AdipoR1, whereas AdipoR1
expression further decreased when it was silenced using AdipoR1
siRNA; furthermore, osmotin was unable to increase its expression
in APP-transfected cells (Supplementary Figure S1d). In addition,
osmotin treatment signiﬁcantly activated AMPK and SIRT1 and
inhibited SREBP2 (sterol-regulatory element-binding protein 2)
and Aβ protein expression in APP-transfected SH-SY5Y cells.
Interestingly, AdipoR1 silencing further reduced AMPK and SIRT1
along with signiﬁcantly increasing SREBP2 and Aβ expression.
Most importantly, AdipoR1 silencing abolished the ability of
osmotin to activate the AMPK and SIRT1 proteins and to inhibit
the SREBP2 and Aβ proteins (Supplementary Figure S1d).
We next analyzed AdipoR1 expression in brain homogenates
from 9- and 12-month-old APP/PS1 mice and 3-month-old
Adipo− /− mice treated with either vehicle or osmotin. The
immunoblot results indicated lower expression of AdipoR1 in
both the 9- and 12-month-old APP/PS1 double-transgenic mice
and in the 3-month-old Adipo− /− mice, whereas osmotin
increased the expression of AdipoR1 in WT and AD mice of both
ages and in Adipo− /− mice (Supplementary Figures S1e and f).
Osmotin induced the activation of AMPK and SIRT1 in both in vitro
and in vivo models
We then studied the expression of activated AMPK (p-AMPKα
(Thr172)) and SIRT1 because they are both cellular energy-sensing
enzymes. We either treated SH-SY5Y cells with Aβ1–42 (5 μM) or
transfected them with APPswe/ind and added osmotin (0.2 μM) for
24 h. Both the Aβ treatment (Figure 1a) and APP transfection
(Figures 1d–f) of these cells resulted in the suppression of p-AMPK
and SIRT1 protein expression and activity (Figures 1b and c),
whereas 0.2 μM osmotin treatment reversed these changes
(Figures 1a–f). Interestingly, the protective effects of osmotin against
the Aβ or APP transfection-induced suppression of p-AMPK and
SIRT1 expression levels and activities could be abolished by
cotreatment with either an AMPK inhibitor, that is, compound C
(20 μM), or the silencing of AMPK with siRNA and a SIRT1 inhibitor,
that is, EX527 (80 μM), or SIRT1 siRNA, respectively, indicating that
the observed protection was not an artifact (Figures 1a–f).
Similarly, we showed that both AMPK and SIRT1 were dependent
on each other because they were both silenced by their respective
siRNAs in APP-transfected SH-SY5Y cells (Figure 1f).
In addition, the levels of p-AMPKα and SIRT1 were lower in the
hippocampi of Adipo− /− mice and APP/PS1 (5-, 9- and 12-month-
old) and APPSW (12-month-old) mice compared with WT mice
(Figure 1g and Supplementary Figure S1e). Accordingly, the
activities of AMPK and SIRT1 were also lower in brain tissues of
Adipo− /− mice and APP/PS1 mice (Figure 1h). Osmotin treatment
for a short period of time increased the p-AMPKα and SIRT1 levels
in the hippocampi of 5-, 9- and 12-month-old APP/PS1 and
12-month-old APPSW mice (Figure 1g). In agreement with these
results, we also observed increases in the activities of AMPK and
SIRT1 in brain homogenates of osmotin-treated APP/PS1 mice and
Adipo− /− mice compared with the respective vehicle-treated mice
(Figure 1h). Similarly, osmotin administration over a long period of
time (2 and 4 weeks) also increased the p-AMPKα and SIRT1 levels
compared with vehicle-treated APP/PS1 mice and Adipo− /− mice,
respectively (Supplementary Figures S1d and e).
Osmotin reduced Aβ production and aggregation by negatively
regulating the levels of cholesterol and SREBP2 in vivo
We ﬁrst examined the total cholesterol, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, free fatty acid
and triglyceride levels in the sera of osmotin-treated and
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vehicle-treated APP/PS1 and Adipo− /− mice to determine the
effects of osmotin on cholesterol levels in these mouse strains
(Supplementary Figure S2a). Our results indicated that osmotin
treatment signiﬁcantly reduced the total cholesterol, low-density
lipoprotein cholesterol, free fatty acid and triglyceride levels and
increased the high-density lipoprotein level compared with
the vehicle-treated APP/PS1 and Adipo− /− mice (Supplementary
Figure S2a).
Next, we performed western blotting to determine the cellular
levels of SREBP2 in the brains of APP/PS1 and Adipo− /− mice. We
showed that compared with WT mice, the levels of SREBP2 were
higher in the hippocampi of vehicle-treated Adipo− /− mice and
APP/PS1 mice at the ages of 5, 9 and 12 months. Osmotin
treatment reduced the levels of SREBP2 in the brain tissues of
Adipo− /− mice and APP/PS1 mice of all ages (5–12 months old)
compared with the vehicle-treated mice (Figure 2a and
Supplementary Figure S2b).
After negatively regulating the cholesterol level, we performed
different techniques to determine whether osmotin affects
the amyloidogenic pathway of Aβ production and deposition in
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Figure 1. Osmotin increased phosphorylated AMP-activated protein kinase (p-AMPK) and sirtuin 1 (SIRT1) levels and their activities in vitro and
in vivo. (a) Western blot analysis of p-AMPK and SIRT1 in lysates of SH-SY5Y cells after treatment with Aβ1–42 (5 μM), osmotin (Os; 0.2 μM),
compound C (C; 20 μM) and EX527 (80 μM) for 24 h and (b, c) their activity histograms. (d–f) Western blot analysis with the respective density
histograms of p-AMPK and SIRT1 in lysates of APPswe/ind-transfected (for 72 h) SH-SY5Y cells subjected to the small interfering RNA
(siRNA)-induced silencing of AMPK and SIRT1 for 48 h, respectively, after 24 h of treatment with Os (0.2 μM). (g) Western blot analyses of
p-AMPK and SIRT1 levels in hippocampal extracts from 5-, 9- and 12-month-old wild-type (WT) and vehicle (Veh)- or Os-treated (for a short
time) amyloid precursor protein/presenilin 1 (APP/PS1) and APPSW mice and (h) AMPK and SIRT activity histograms in brain homogenates of
Adipo− /− and APP/PS1 mice. The assays were performed three times with similar results, and representative data from one experiment with
triplicate samples are shown. The bands were quantiﬁed using Sigma Gel System (SPSS, Chicago, IL, USA), and their differences are presented
as histograms derived from a one-way analysis of variance (ANOVA) followed by a t-test and as the mean± s.e.m. for the respective indicated
proteins (n= 5/group). After developing of respective antibodies, membranes were reprobed for the β-actin signal, shown as the loading
control. Histograms depict analyses of band density relative to the density of WT on the same blot. Signiﬁcance: *Po0.05, **Po0.01 and
***Po0.001.
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APP/PS1 mice of different ages. Western blot analysis of protein
extracts showed that the levels of APP, the amyloidogenic
β-secretase BACE1 and Aβ were higher in the brain tissues of
vehicle-treated APP/PS1 mice of different ages, including
5-, 9- and 12-month-old mice. Conversely, osmotin administration
signiﬁcantly lowered the levels of these proteins, as shown in the
results obtained using brain tissues from APP/PS1 mice (Figure 2a).
The levels of soluble Aβ1–42 and Aβ1–40 were measured using
enzyme-linked immunosorbent assay in brain homogenates of
transgenic mice after osmotin treatment, and the results indicated
that osmotin treatment signiﬁcantly reduced the levels of soluble
Aβ1–42 and Aβ1–40 in the hippocampi and cortices of APP/PS1 mice
(Figures 2b and c).
In addition, we performed thioﬂavin S and Aβ antibody (6E10)
immunostaining to examine both 12- and 16-month-old APP/PS1
mouse brains after osmotin administration for 4 weeks. The results
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Figure 2. Osmotin reduced amyloid burden by inhibiting SREBP2 (sterol regulatory element-binding protein 2) expression in amyloid
precursor protein/presenilin 1 (APP/PS1) mice. (a) Western blot analysis of SREBP2, BACE1, APP and amyloid-β (Aβ) levels in hippocampal and
cortex extracts from 5-, 9- and 12-month-old wild-type (WT) and vehicle (Veh)- or osmotin (Os)-treated (for a short time) APP/PS1 mice.
Representative blots and histograms depicting analyses of band density relative to WT bands are shown. The membranes were reprobed for
β-actin as a housekeeping control. The bars indicate the mean± s.e.m. (n= 5/group). (b, c) Enzyme-linked immunosorbent assay (ELISA)
histograms (relative) of soluble (b) Aβ1–42 and (c) Aβ1–40 in cortex and hippocampal brain homogenates of APP/PS1 mice with or without
osmotin treatment. All of the methods and procedures recommended by the manufacturer were followed, and experiments were performed
in triplicate. (d, e) Fluorescence images with relative density histograms of cortex and hippocampal regions of 12- and 16-month-old Veh- and
Os-treated (4 weeks) APP/PS1 mice, indicating the localization of (d) Aβ plaques and (e) Aβ (6E10) aggregates. Signiﬁcance: *Po0.05,
**Po0.01 and ***Po0.001.
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indicated that osmotin signiﬁcantly reduced the amounts of
Aβ aggregation and deposition in the cortices and hippocampi
of APP/PS1 mice after osmotin administration for 4 weeks
(Figures 2d and e).
Osmotin reduced the amyloidogenic pathway of Aβ production in
an AMPK/SIRT1/SREBP2-dependent manner in vitro
To examine the detailed mechanism of osmotin reduction via the
amyloidogenic pathway, we transfected SH-SY5Y cells with
APPswe/ind for 72 h. The results indicated that osmotin treatment
for 24 h signiﬁcantly reduced the expression of APP and Aβ in
APPswe/ind-transfected SH-SY5Y cells. Interestingly, when both
AMPK and SIRT1 were silenced with their respective siRNAs, the
APP and Aβ levels were further signiﬁcantly increased, and
osmotin was unable to reduce their expression levels (Figure 3a).
In accordance with these ﬁndings, the APP level was also
increased in cells containing AMPK siRNA, but it was dramatically
decreased in cells containing SREBP2 siRNA (Figure 3b).
In addition, we assessed the expression of BACE1 and SREBP2 in
APPswe/ind-transfected SH-SY5Y cells. It was evident from
the blot results that the expression levels of both BACE1 and
SREBP2 in cell lysates were increased as a result of APP
transfection; however, when AMPK was silenced by siRNA, the
expression levels of both BACE1 and SREBP2 further increased,
and the suppressive ability of osmotin was abolished (Figure 3c).
We then silenced SREBP2 with siRNA and measured the BACE1
and SREBP2 levels in APP-transfected SH-SY5Y cells. The results
indicated that after APP transfection, the expression levels of both
BACE1 and SREBP2 were signiﬁcantly higher compared with the
control, and when SREBP2 was silenced by siRNA, the expression
levels of BACE1 and SREBP2 were dramatically decreased
(Figure 3d).
Osmotin enhanced the non-amyloidogenic gene ADAM10 in an
AMPK/SIRT1-dependent manner both in vivo and in vitro
Similarly, the protein levels of sAPP-α, ADAM10 and ADAM17 were
lower in the brain tissues of vehicle-treated APP/PS1 mice
compared with WT mice. The levels of sAPP-α and the
α-secretases ADAM10 and ADAM17 were signiﬁcantly higher in
the brain tissues of osmotin-treated APP/PS1 mice compared with
vehicle-treated controls (Figure 3e). To determine whether the
beneﬁcial effect of osmotin on the non-amyloidogenic pathway is
also AMPK and SIRT1 dependent, we measured ADAM10 levels in
APP-transfected SH-SY5Y cells and in cells following AMPK and
SIRT1 siRNA-induced silencing. The results indicated that the
expression of ADAM10 was decreased in APP-transfected cells and
was enhanced by osmotin; however, when AMPK and SIRT1 were
silenced with their respective siRNAs, ADAM10 expression was
further dramatically decreased, and the suppressive ability of
osmotin was also blocked (Figures 3f–h), indicating that the
neuroprotective functions of osmotin may be mediated by AMPK
and SIRT1 (Figures 3f–h).
Osmotin protected against the loss of NMDA receptors and
NMDAR activity in APP/PS1 mice
The expression levels of both N-methyl-D-aspartate receptors
NMDAR1 (NR1) and NMDAR2 (NR2), which control synaptic
plasticity, synapse formation and memory function, were
measured with western blotting. Reduced levels of NR1 and NR2
were observed in the brain tissues of vehicle-treated APP/PS1
mice, whereas osmotin treatment increased the levels in the brain
tissues of APP/PS1 mice (Supplementary Figures S3a and b). A
previous study has reported that synaptosomal-associated protein
of 23 kDa (SNAP-23) and SNAP-25 are important for the trafﬁcking
of NMDARs to the cell surface. Western blot analysis of tissue
extracts (Supplementary Figure S3a) and immunoﬂuorescence
analyses of tissue sections (Supplementary Figure S3b) conﬁrmed
that the levels of SNAP23, SNAP25, synaptophysin and PSD95 in
the hippocampi and cortices of the brains of vehicle-treated
APP/PS1 mice were lower than those in the hippocampi and
cortices of the brains of WT mice and that osmotin treatment
protected the APP/PS1 mice against these decreases
(Supplementary Figures S3a and b). In the hippocampus, these
trends for synaptophysin and SNAP23 were observed in the
dentate gyrus and CA1 regions.
Osmotin augmented the number of functional synapses without
affecting synaptic strength and rescued LTP deﬁcits in AD models
To investigate whether osmotin has an effect on the plasticity of
functional synapses, we measured α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor-mediated miniature
excitatory postsynaptic currents (mEPSCs) in cultured hippocam-
pal cells at 21 days in vitro following 24 h of treatment with
osmotin (8 to 32 nM) or vehicle. Osmotin (16 and 32 nM)
signiﬁcantly increased the mean frequency of mEPSCs compared
with vehicle-treated controls. However, osmotin treatment
had little effect on the mean amplitudes of AMPAR-mediated
mEPSCs in all osmotin-treated groups, suggesting that this
treatment did not induce alterations in postsynaptic strength
(Supplementary Figure S4a1). Next, to investigate the effects of
osmotin on synaptic function under Alzheimer’s disease-like
pathological conditions, we measured AMPAR-mediated mEPSCs
in hippocampal cells at 21 days in vitro following 24 h of treatment
with vehicle, Aβ1–42 (0.05 μg ml
− 1) or Aβ1–42 (0.05 μg ml
− 1) plus
osmotin (32 nM). As reported previously, Aβ signiﬁcantly
decreased the mean frequency of AMPAR-mediated mEPSCs
compared with the vehicle-treated control, whereas osmotin
(32 nM) reversed the effects of Aβ (Supplementary Figure S4b1).
Moreover, there were no signiﬁcant differences in mean
mEPSC amplitudes between the vehicle group and the Aβ or Aβ
plus osmotin groups, indicating that these treatments did not
induce signiﬁcant alterations in postsynaptic strength.
To investigate the effect of osmotin on the plasticity of functional
synapses in an ex vivo preparation, we measured AMPA-mediated
mEPSCs in the hippocampal CA1 region in acute slices prepared
from WT, vehicle-treated transgenic AD (APP/PS1) and osmotin-
treated APP/PS1 mice. As shown in Figure 4a1 and 3, the mean
frequency of mEPSCs was signiﬁcantly reduced in the APP/PS1
mice compared with the WT mice, as expected. Surprisingly,
osmotin signiﬁcantly reversed the reduction in AMPA-mediated
mEPSCs almost to the level observed in the WT mice (14.4 ± 2.0 Hz,
n=7 for WT; 7.5 ± 1.0 Hz, n=6 for APP/PS1+vehicle; 13.91 ± 1.3 Hz,
n= 6 for APP/PS1+osmotin; one-way ANOVA with post hoc Tukey’s
test, WT versus APP/PS1+vehicle, Po0.05; APP/PS1+vehicle
versus APP/PS1+osmotin, Po0.05) (Figure 4a3). However,
osmotin treatment had little effect on the mean amplitude of
AMPA-mediated mEPSCs in all the osmotin-treated groups,
suggesting that there were no postsynaptic alterations in synaptic
strength (4.4 ± 0.3 pA, n= 7 for WT; 4.9 ± 0.2 pA, n= 6 for APP/PS1
+vehicle; 4.5 ± 0.2 pA, n= 6 for APP/PS1+osmotin; one-way
ANOVA, P40.05) (Figure 4a2 and 3).
In addition, we investigated whether the improvement in
cognitive performance following osmotin treatment was
associated with the modulation of synaptic function and plasticity.
To this end, we performed electrophysiology experiments using
acute hippocampal slices prepared from WT, vehicle-treated
transgenic AD (APP/PS1) and osmotin-treated APP/PS1 mice. At
Schaffer collateral inputs to CA1, long-term potentiation (LTP) was
signiﬁcantly suppressed in the hippocampal CA1 regions of
APP/PS1 mice compared with WT mice (Figure 4b1 and 2).
Surprisingly, osmotin reversed the suppressed LTP responses in
the hippocampal CA1 regions of APP/PS1 mice, increasing them to
the WT level (92.0 ± 9.6% increase, n= 3 for WT; 32.0 ± 8.5%
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increase, n= 4 for APP/PS1+vehicle; 85.0 ± 15.4% increase, n= 4 for
APP/PS1+osmotin; one-way ANOVA with post hoc Tukey’s test; WT
versus APP/PS1+vehicle, Po0.05; APP/PS1+vehicle versus APP/
PS1+osmotin, Po0.05) (Figure 4b3 and 4). These data suggest
that osmotin treatment restored synaptic plasticity and the
number of functional synapses, which are signiﬁcantly deterio-
rated in AD, implying a role for osmotin in improving memory and
cognition.
Osmotin protected against memory and cognitive deﬁcits in APP
and APP/PS1 mice
Finally, we examined the effects of osmotin on hippocampal-
dependent memory and cognition in single (APP) and double-
transgenic (APP/PS1) mice using the MWM and Y-maze tasks.
During the session before treatment, the escape latency from the
water to the submerged platform was signiﬁcantly higher for all of
the animals, including the WT and transgenic APP and APP/PS1
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Figure 3. Osmotin (Os) reduced amyloid-β (Aβ) production in APPswe/ind-transfected SH-SY5Y cells in an AMPK/SIRT1/SREBP2-dependent
manner. Western blot analysis and respective density histograms of (a) amyloid precursor protein (APP) and Aβ, (b) APP and (c, d) BACE1 and
SREBP2 (sterol regulatory element-binding protein 2) in APPswe/ind-transfected SH-SY5Y cells subjected to the small interfering RNA (siRNA)-
induced silencing of AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1) and SREBP2, respectively. Cells were transfected for 72 h followed
by siRNA treatment for 48 h and osmotin treatment for 24 h. The β-actin signal is shown as a loading control. (e) Osmotin treatment increased
the levels of sAPP-α, ADAM10 and ADAM17 protein expression in brain tissues homogenates from 9-month-old APP/presenilin 1 (PS1) mice
compared with vehicle-treated mice. (f–h) ADAM10 western blot analyses and respective density histograms of APPswe/ind-transfected
SH-SY5Y cells subjected to the siRNA-induced silencing of AMPK and SIRT1. All the respective details are described in the Materials and
methods section. Signiﬁcance: *Po0.05, **Po0.01 and ***Po0.001.
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mice, compared with day 1 of treatment, whereas the WT mice
learned the task quickly, as shown by a sharp decrease in escape
latency. However, the APP and APP/PS1 mice showed learning
deﬁcits on days 2 and 3 that were consistent with the reported
spatial learning and memory deﬁcits in APP/PS1 mice, as shown in
Figure 5a and Supplementary Figure S5a.
The administration of osmotin to the APP and APP/PS1 mice
resulted in a signiﬁcant reduction in the mean escape latency time
compared with the untreated mice. The histograms show that the
decrease in the mean escape latency started on day 1 and
continued until days 3 and 7 for the APP and APP/PS1 mice,
respectively, and was persistent compared with the vehicle-
treated APP and APP/PS1 mice (Figure 5b and Supplementary
Figure S5a). The mice were allowed a 2-day rest period after the
training period before being subjected to a probe test with
the removal of the platform. In the probe test, time spent in the
quadrant that previously contained the hidden platform was
determined as a measure of memory function. The results showed
that the vehicle-treated control mice spent the longest time in the
target quadrant, followed by the osmotin-treated APPsw and
APP/PS1 mice; the vehicle-treated APPsw and APP/PS1 mice
spent the shortest time. These results conﬁrmed that osmotin
ameliorated hippocampal spatial memory deﬁcits in the APPsw
and APP/PS1 mice (Figure 5c and Supplementary Figure S5b).
Next, the Y-maze test was performed to determine the effects of
osmotin on short-term spatial memory loss in APPsw and
APP1/PS1 mice. The spontaneous alternation rate from the center
of the maze, which is measured as the percentage of the total
number of arm entries that can be counted as nonrepetitive
triplets, showed that the APPsw and APP/PS1 mice had a lower
percentage of alternations than the WT control mice, indicating
less working memory capacity. The percentage of alternations of
the APPsw and APP/PS1 mice increased after osmotin treatment,
showing that this treatment reduced the short-term spatial
memory deﬁcit in the APPsw and APP/PS1 mice (Figure 5d and
Supplementary Figure S5c).
DISCUSSION
To the best of our knowledge, this is the ﬁrst report describing
how osmotin is involved in improving synapses, memory and
cognition; reversing reductions in LTP; and diminishing the
burden of Aβ by reducing cholesterol biosynthesis in APP/PS1
AD model mice. The beneﬁcial effects of osmotin are correlated
with its ability to modulate AdipoR1, activate AMPK and SIRT1 and
Figure 4. Osmotin (Os) augmented the number of functional synapses without affecting synaptic strength and rescued long-term
potentiation (LTP) deﬁcits in the CA1 region of hippocampal slices from Alzheimer’s disease (AD) mice. (aa1) Representative traces of
spontaneous unitary excitatory postsynaptic currents (EPSCs) recorded in the CA1 region of hippocampal slices from wild-type (WT; left trace),
amyloid precursor protein/presenilin 1 (APP/PS1) and osmotin-treated APP/PS1 (right trace) mice. (a2, left) Cumulative miniature EPSC
(mEPSC) amplitude distributions from all recorded neurons for the three mouse groups (control (black circle), APP/PS1 (red trace) and
osmotin-treated APP/PS1 (blue circle) groups). (a2, right) Summary of mEPSC amplitudes for the three groups. (a3, left) Cumulative mEPSC
frequency distributions from all recorded neurons for the three groups. (a3, right) Summary of mEPSC amplitudes for the three groups.
Summary of mEPSC frequencies in control APP/PS1 and osmotin-treated APP/PS1 mice. (b1, 2, 3, upper trace) A representative trace of LTP
induction in the CA1 region of the hippocampi of control mice, APP/PS1 mice and osmotin-treated APP/PS1 mice, respectively. (b1, 2, 3, lower
trace) Average time course of LTP induction in the CA1 region of the hippocampi of control, APP/PS1 mice and osmotin-treated APP/PS1 mice,
respectively. (b4) Summary of the effects of osmotin on LTP induction in APP/PS1 mice. The bars represent the mean± s.e.m. (n= 8).
Signiﬁcance: *Po0.05.
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downregulate SREBP2 to block the amyloidogenic pathway of Aβ
production.
The search for new therapeutic agents for the prevention of Aβ
toxicity has included agents that block the generation of Aβ,
minimize its accumulation or activate the process of Aβ clearance
from the entire brain or parts of the brain. Our ﬁnding that
osmotin modulated AdipoR1 in both in vitro and in vivo animal
models demonstrates that AdipoR1 is involved in the progression
of AD. Furthermore, the osmotin-treated Adipo− /− mouse
results fully support our current proposed mechanism of the
beneﬁcial effects of osmotin in neurodegenerative diseases such
as AD. In the present study, we observed striking differences in the
expression of AdipoR1 and other proteins in AD and in
Adipo− /− mice after osmotin administration for either a short or
long duration. All of these results are of clinical signiﬁcance and
are likely to have important implications in the pathogenesis of
this disease because, presently, there are no such data. In this
regard, leptin, an adipokine, has been reported to cause a
reduction in Aβ via AMPK activation in vitro and to attenuate
memory impairment in in vivo AD models.19,20 Similarly, we
showed that osmotin, which is a homolog of adiponectin,
can potentially inhibit the amyloidogenic pathway of the
Aβ-synthesizing machinery. We examined brain tissues of
5-, 9-, 12- and 16-month-old APP/PS1 mice using different
techniques, such as enzyme-linked immunosorbent assay, western
blotting, immunohistochemistry and immunoﬂuorescence.
Collectively, our data demonstrate that osmotin treatment can
reduce the accumulation of Aβ peptides and the formation of
extracellular Aβ-containing senile plaques in middle- and
late-stage AD. Most importantly, we observed that osmotin
treatment activated AMPK and SIRT1 both in vitro and in vivo
(including both Adipo− /− and APP/PS1 mice) as AMPK and SIRT1
regulate each other and share downstream targets.9 Several lines
of evidence indicate that the AMPK/SIRT1 axis is involved in
regulating Aβ levels in brain tissues. For example, downregulation
of the expression of PP2Ca, a major AMPK phosphatase, by dietary
quercetin leads to AMPK activation, reduced BACE1 expression, Aβ
production and the deposition of Aβ in the brains of mice fed a
high cholesterol diet.21 AMPK directly interacts with and
phosphorylates SREBP-1c and SREBP-2 to prevent their cleavage
and nuclear translocation, thereby downregulating the transcrip-
tion of SREBP target genes, such as those involved in cholesterol
and fatty acid biosynthesis.22 Thus, in agreement with previous
studies, we found that osmotin treatment not only downregulated
the abundance of total cholesterol, triglycerides, and free fatty
acids in serum, but also most speciﬁcally reduced cholesterol
biogenesis in the brains of Adipo− /− and APP/PS1 mice, both by
inhibiting SREBP activity via the activation of AMPK/SIRT1 and by
reducing the level of the transcription factor SREBP2. Reduced
cholesterol levels in lipid rafts attenuate the activities of
Aβ-synthesizing enzymes.23–25 Thus, we found that osmotin
regulated the activities of an Aβ-synthesizing enzyme (BACE1)
via activated AMPK/SIRT1 and negatively regulated the SREBP2
pathway. Excess cholesterol in APP/PS1 mice induces amyloido-
genesis, and drugs that inhibit cholesterol biogenesis have
protective effects against amyloidogenesis.26,27 SREBPs are key
transcription factors involved in the regulation of lipid synthesis. It
has been reported that SREBPs are overexpressed in APP/PS1 mice
and that the overexpression of SREBP-2 in these mice results in AD
pathologies.28 The AMPKSIRT1 axis regulates lipid biosynthesis.
SREBPs are substrates of AMPK, and the phosphorylation of
SREBPs inhibits their lipidogenic activities.22 SREBPs are also
After Treatment
a
c
***
b
******
*****
**
*
*
d
***
Figure 5. Osmotin (Os) diminished hippocampus-dependent spatial memory deﬁcits in amyloid precursor protein/presenilin 1 (APP/PS1)
mice. Escape latency (a) before osmotin treatment during the training period (submerged platform) and (b) after treatment in the Morris
water maze (MWM) test. The escape latency of the training days was determined using repeated-measures analysis of variance (ANOVA). The
data represent mean± s.e.m. (n= 10/group). (c) The time spent in the target quadrant during the MWM probe test (platform removed) is
expressed as the percentage of alternation. (d) The histogram shows the results of the Y-maze spontaneous alternation test performed to
assess the effect of osmotin treatment on short-term memory in double-transgenic APP/PS1 Alzheimer’s disease (AD) model mice. The data
represent mean± s.e.m. (n= 10/group). Signiﬁcance: *Po0.05, **Po0.01 and ***Po0.001.
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substrates of SIRT1, and deacetylation by SIRT1 promotes their
proteasomal degradation, thereby inhibiting their lipidogenic
activities.29 In addition, we found that osmotin treatment
increased the levels of the α-secretases ADAM10 and ADAM17
that cleave the middle of the Aβ domain to preclude Aβ
formation. The cleavage of APP by α-secretases generates
sAPP-α, a neuroprotective extracellular fragment of APP. Osmotin
treatment increased the levels of sAPP-α in the brain tissues of
APP/PS1 mice, indicating that it increased α-secretase activity.
Synapses and dendritic spines, through which neurons
communicate signals with each other, are especially vulnerable
to AD. Cognitive decline in AD is associated with synaptic
dysfunction and alterations in the number and shapes of dendritic
spines, rather than with neuronal loss.30 The ionotropic glutamate
receptors AMPAR and NMDAR are contained in excitatory
synapses in dendritic spines. AD brains are characterized by the
loss and degeneration of dendritic spines as well as the induction
of LTP. This association has been established both in vivo in
transgenic mice and in vitro in neuronal cells exposed to
AD-causing agents.31,32 Considerable evidence shows that the
accumulation of soluble Aβ in AD causes synaptic dysfunction,
leading to AMPAR removal and the loss of dendritic spines.33
We observed that osmotin treatment reduced Aβ levels,
attenuated NMDAR loss and, most importantly, attenuated LTP
in APP/PS1 mice that was correlated with cognitive and memory
improvements.
Our results are consistent with the amelioration of
hippocampal-dependent memory dysfunction in AD mice34 by
osmotin. Importantly, osmotin induced decreases in memory
deﬁcits, accompanied not only by a signiﬁcant reduction in the
amyloid burden but also by evident plaque fragmentation in the
brains of transgenic mice. Similarly, our study also showed that
osmotin reversed AMPA-mediated mEPSCs in in vitro cultured
neurons, diminished the effects of Aβ and ameliorated the
suppression of LTP in AD mice in vivo. Hence, osmotin may
improve cognitive performance in transgenic mice (both APP and
APP/PS1) by altering the processing of Aβ peptides, decreasing
the amyloid burden, abrogating related apoptosis and neurode-
generation within the hippocampus and/or directly promoting
memory formation and synaptic plasticity. Our data fully support
the ability of osmotin to ameliorate AD-like pathological pathways,
and they demonstrate its efﬁcacy in reverting or preventing
cognitive deterioration in APP/PS1 mice. Based on its safety and
brain bioavailability, osmotin appears to be a promising drug for
the prevention of AD. The outcomes of our study warrant further
investigation of osmotin-like proteins or their derivatives as
candidates for AD therapies based on the modiﬁcation or delay
of the onset of Aβ pathology.
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